Co-Authors
This is a "connection" page, showing publications co-authored by Kathleen Brady and Bryan Tolliver.
Connection Strength
3.004
-
A randomized, double-blind, placebo-controlled clinical trial of acamprosate in alcohol-dependent individuals with bipolar disorder: a preliminary report. Bipolar Disord. 2012 Feb; 14(1):54-63.
Score: 0.428
-
Cognitive enhancers in the treatment of substance use disorders: clinical evidence. Pharmacol Biochem Behav. 2011 Aug; 99(2):285-94.
Score: 0.406
-
Determinants of cue-elicited craving and physiologic reactivity in methamphetamine-dependent subjects in the laboratory. Am J Drug Alcohol Abuse. 2010 Mar; 36(2):106-13.
Score: 0.375
-
Reversible elevation of triglycerides in dual-diagnosis patients taking aripiprazole: a case series. J Clin Psychopharmacol. 2008 Aug; 28(4):464-7.
Score: 0.336
-
Treatment of patients comorbid for addiction and other psychiatric disorders. Curr Psychiatry Rep. 2007 Oct; 9(5):374-80.
Score: 0.317
-
Comorbid anxiety disorders and baseline medication regimens predict clinical outcomes in individuals with co-occurring bipolar disorder and alcohol dependence: Results of a randomized controlled trial. Psychiatry Res. 2021 Jan; 295:112904.
Score: 0.188
-
Does alexithymia explain variation in cue-elicited craving reported by methamphetamine-dependent individuals? Am J Addict. 2012 Mar-Apr; 21(2):130-5.
Score: 0.108
-
Impaired cognitive performance in subjects with methamphetamine dependence during exposure to neutral versus methamphetamine-related cues. Am J Drug Alcohol Abuse. 2012 May; 38(3):251-9.
Score: 0.107
-
Impact of depressive symptoms on future alcohol use in patients with co-occurring bipolar disorder and alcohol dependence: a prospective analysis in an 8-week randomized controlled trial of acamprosate. Alcohol Clin Exp Res. 2012 Mar; 36(3):490-6.
Score: 0.104
-
The impact of clinical and demographic variables on cognitive performance in methamphetamine-dependent individuals in rural South Carolina. Am J Addict. 2011 Sep-Oct; 20(5):447-55.
Score: 0.103
-
Comorbid anxiety disorders and baseline medication regimens predict clinical outcomes in individuals with co-occurring bipolar disorder and alcohol dependence: Results of a randomized controlled trial. Psychiatry Res. 2011 Aug 15; 188(3):361-5.
Score: 0.102
-
Predictors of clinical trial dropout in individuals with co-occurring bipolar disorder and alcohol dependence. Drug Alcohol Depend. 2011 Nov 01; 118(2-3):493-6.
Score: 0.102
-
Extinction of drug cue reactivity in methamphetamine-dependent individuals. Behav Res Ther. 2010 Sep; 48(9):860-5.
Score: 0.095
-
Biologic Commonalities between Mental Illness and Addiction. Prim psychiatry. 2009 Aug 01; 16(8):33-39.
Score: 0.090
-
Alcohol use and anxiety: diagnostic and management issues. Am J Psychiatry. 2007 Feb; 164(2):217-21; quiz 372.
Score: 0.076
-
Independent predictors for lifetime and recent substance use disorders in patients with rapid-cycling bipolar disorder: focus on anxiety disorders. Am J Addict. 2010 Sep-Oct; 19(5):440-9.
Score: 0.024
-
Clinical correlates of patients with rapid-cycling bipolar disorder and a recent history of substance use disorder: a subtype comparison from baseline data of 2 randomized, placebo-controlled trials. J Clin Psychiatry. 2008 Jul; 69(7):1057-63.
Score: 0.021
-
Differential interactions between comorbid anxiety disorders and substance use disorder in rapid cycling bipolar I or II disorder. J Affect Disord. 2008 Sep; 110(1-2):167-73.
Score: 0.020